URGN
What one share of UroGen Pharma holds
Pharmaceutical Preparations
We are a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers. We have developed RTGel reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based technology that has the potential to improve therapeutic profiles of existing drugs.
UroGen Pharma’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $3.82 |
|---|---|
| Profit | −$1.97 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$3.22 |
| Cash and investments | $1.62 |
| Debt | $3.95 |
| Book value | −$2.71 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$1.91 | $0.30 | $1.52 | — | $7.07 |
| 2017 | — | −$2.14 | $0.03 | −$1.01 | — | $4.98 |
| 2018 | — | −$4.80 | $0.04 | −$2.41 | — | $5.56 |
| 2019 | — | −$5.12 | $0.02 | −$3.48 | — | $8.58 |
| 2020 | $0.54 | −$5.90 | $0.06 | −$4.92 | — | $4.35 |
| 2021 | $2.15 | −$4.96 | $0.03 | −$3.83 | — | $0.37 |
| 2022 | $2.82 | −$4.81 | $0.01 | −$3.85 | — | −$3.86 |
| 2023 | $2.87 | −$3.55 | $0.01 | −$2.66 | — | −$2.01 |
| 2024 | $2.11 | −$2.96 | $0.01 | −$2.26 | — | −$0.21 |
| 2025 | $2.28 | −$3.19 | $0.01 | −$3.38 | — | −$2.18 |